COMPOSITIONS FOR PRESERVATION OF VIRAL VECTORS
Compositions and methods for the preservation and long-term storage of viral vectors such as lentiviral vectors are provided.
1 . A preservation composition for preserving viral vectors, comprising a first preservation reagent and a second preservation reagent,
wherein the first preservation reagent comprises sucrose at a concentration of 100 g/L to 250 g/L, potassium dihydrogen phosphate or sodium dihydrogen phosphate at a concentration of 0.8 mmol/L to 1.2 mmol/L, disodium hydrogen phosphate or dipotassium hydrogen phosphate at a concentration of 2.6 mmol/L-3.2 mmol/L, and sodium chloride at a concentration of 8.5-10 g/L,
wherein the second preservation reagent comprises sucrose at a concentration of 100 g/L to 250 g/L, albumin at a concentration of 40 g/L to 300 g/L, sodium caprylate or potassium caprylate at a concentration of 4 mmol/L to 20 mmol/L, sodium N-acetyltryptophan or potassium N-acetyltryptophan at a concentration of 4 mmol/L to 20 mmol/L, potassium dihydrogen phosphate or sodium dihydrogen phosphate at a concentration of 0.1 mmol/L-1.2 mmol/L, disodium hydrogen phosphate or dipotassium hydrogen phosphate at a concentration of 0.5 mmol/L-3 mmol/L, and sodium chloride at a concentration of 1.5-10 g/L.
2 . The preservation composition of claim 1 , comprising sucrose at a concentration of 100 g/L to 250 g/L, albumin at a concentration of 20 g/L to 150 g/L, sodium caprylate or potassium caprylate at a concentration of 1.6 mmol/L to 10 mmol/L, sodium N-acetyltryptophan or potassium N-acetyltryptophan at a concentration of 1.6 mmol/L to 10 mmol/L, potassium dihydrogen phosphate or sodium dihydrogen phosphate at a concentration of 0.5 mmol/L to 1 mmol/L, disodium hydrogen phosphate or dipotassium hydrogen phosphate at a concentration of 1.6 mmol/L to 3 mmol/L, and sodium chloride at a concentration of 5.5-10 g/L.
3 . The preservation composition of claim 1 , wherein the first preservation reagent and the second preservation reagent have a volume ratio ranging from about 1:1 to about 4:1.
4 . The preservation composition of claim 1 , wherein the first preservation reagent and the second preservation reagent are separate or mixed.
5 . The preservation composition of claim 1 , having an osmotic pressure ranging from about 900 mOsmol/kg to about 1400 mOsmol/kg.
6 . The preservation composition of claim 1 , having a pH ranging from about 6.95 to about 7.45.
7 . The preservation composition of claim 1 , further comprising viral vectors.
8 . The preservation composition of claim 1 , wherein the viral vectors are retroviral vectors.
9 . The preservation composition of claim 1 , wherein the retroviral vectors are lentiviral vectors.
10 . The preservation composition of claim 1 , wherein the lentiviral vectors are selected from the group consisting of human immunodeficiency virus (HIV); visna-maedi virus (VMV); caprine arthritis-encephalitis virus (CAEV); equine infectious anemia virus (EIAV); feline immunodeficiency virus (FIV); bovine immune deficiency virus (BIV); and simian immunodeficiency virus (SIV).
11 . The preservation composition of claim 1 , wherein the lentiviral vectors are HIV-1 or HIV-2.
12 . A method for preserving viral vectors, the method comprising combining the preservation composition of claim 1 with the viral vectors.
13 . A method for preserving viral vectors using the preservation composition of claim 1 , the method comprising:
(a) combining the first preservation reagent with the viral vectors to form a mixture; and
(b) combining the second preservation reagent with the mixture of step (a).
14 . The method of claim 13 , wherein the first preservation reagent and the second preservation reagent have a volume ratio ranging from about 1:1 to about 4:1.
15 . A method of transducing a cell, the method comprising contacting the cell with the preservation composition of claim 7 .
16 . The method of claim 15 , wherein the cell is a human cell.
17 . The method of claim 15 , wherein the cell is a stem cell or progenitor cell.
18 . The method of claim 15 , wherein the cell is a hematopoietic cell.
19 . The method of claim 18 , wherein the hematopoietic cell is a lymphocyte.
20 . The method of claim 19 , wherein the lymphocyte is a T lymphocyte.